Valneva SE
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas Lingelbach
- Full Time Employees
- 674
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6 rue Alain Bombard Saint-Herblain GE France 44800
- IPO Date
- Apr 23, 2010
- CIK
- 0001836564
- Website
- valneva.com
- Similar Companies
- Business
- Valneva SE is a specialized biotechnology firm dedicated to creating and distributing preventative immunizations for various infectious diseases where medical solutions remain insufficient. Its currently marketed vaccines include IXIARO, providing protection against Japanese encephalitis; DUKORAL, an oral solution to prevent cholera and certain types of traveler's diarrhea caused by ETEC; and IXCHIQ, a vaccine targeting the chikungunya virus. While IXCHIQ has obtained marketing authorizations in Europe, Canada, the United Kingdom, and Brazil, its license in the United States was temporarily suspended by the FDA in August 2025 following reports of serious adverse events. The company maintains a robust development pipeline, featuring VLA15, a Lyme disease vaccine candidate currently in advanced Phase 3 clinical trials, co-developed with Pfizer. Results from these crucial trials are anticipated in the first half of 2026, with regulatory submissions expected later that year. Other key candidates include S4V2, a leading Shigella vaccine candidate with Fast Track designation from the FDA, and VLA1601, a Zika virus vaccine candidate in Phase 1 development. Valneva distributes its commercial products across the United States, Canada, Europe, and other international markets. The firm was established in 1998 and is headquartered in Saint-Herblain, France.
Company News
Valneva SE (VALN) Q1 2026 Earnings Call Transcript
VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026
Declaration of shares and voting rights of Valneva SE – March 2026
An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
Valneva SE (VALN) Q4 2025 Earnings Call Transcript
VALNEVA Declaration of shares and voting rights: February 28, 2026
VALNEVA Declaration of shares and voting rights: January 31, 2026
Valneva withdraws application for standard US approval of its chikungunya shot
Valneva SE - Declaration of voting rights - December 2025
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
VALNEVA Declaration of shares and voting rights: November 30, 2025
Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings
Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study
Valneva SE (VALN) Q3 2025 Earnings Call Transcript
VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the Firm
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday